Database : MEDLINE
Search on : Rhabdomyosarcoma [Words]
References found : 15812 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 1582 go to page                         

  1 / 15812 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 29501533
[Au] Autor:Bukchin A; Pascual-Pasto G; Cuadrado-Vilanova M; Castillo-Ecija H; Monterrubio C; Olaciregui NG; Vila-Ubach M; Ordeix L; Mora J; Carcaboso AM; Sosnik A
[Ad] Address:Laboratory of Pharmaceutical Nanomaterials Science, Department of Materials Science and Engineering, Technion-Israel Institute of Technology, 3200003 Haifa, Israel.
[Ti] Title:Glucosylated nanomicelles target glucose-avid pediatric patient-derived sarcomas.
[So] Source:J Control Release;276:59-71, 2018 Feb 28.
[Is] ISSN:1873-4995
[Cp] Country of publication:Netherlands
[La] Language:eng
[Ab] Abstract:We report for the first time on a nano-drug delivery system based on glucosylated polymeric nanomicelles to actively target the second-generation tyrosine kinase inhibitor dasatinib to glucose-avid pediatric sarcomas by the intravenous route. After a comprehensive physicochemical characterization that confirmed the substantially lower critical micellar concentration and the higher encapsulation capacity of the glucosylated amphiphilic nanocarrier with respect to the pristine counterpart, we showed a 9-fold decrease of the half maximal inhibitory concentration of dasatinib in a rhabdomyosarcoma cell line, Rh30, in vitro. In immunodeficient mice bearing the glucose-avid Rh30 xenograft, we revealed that the glucosylated polymeric nanomicelles increased the delivery of dasatinib in the tumor parenchyma. Conversely, the exposure of off-target tissues and organs to the drug was substantially reduced. Upon experimental confirmation that most patient-derived xenograft (PDX) models of pediatric sarcomas overexpress glucose transporter 1 (GLUT-1), we demonstrated the selective accumulation of dasatinib in a patient-derived rhabdomyosarcoma model in vivo. Conversely, the reference dose administered by the oral route was not tumor-selective. Finally, the improved nanocarrier pharmacokinetics led to prolonged median survival of mice bearing a clinically relevant PDX model of alveolar rhabdomyosarcoma from 19 days for the untreated controls to 27 days for the targeted therapy.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180310
[Lr] Last revision date:180310
[St] Status:Publisher

  2 / 15812 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29445192
[Au] Autor:Saini M; Verma A; Mathew SJ
[Ad] Address:Laboratory of Developmental Genetics, Regional Centre for Biotechnology, NCR Biotech Science Cluster, 3rd Milestone, Faridabad-Gurgaon Expressway, Faridabad, Haryana, 121001, India.
[Ti] Title:SPRY2 is a novel MET interactor that regulates metastatic potential and differentiation in rhabdomyosarcoma.
[So] Source:Cell Death Dis;9(2):237, 2018 Feb 14.
[Is] ISSN:2041-4889
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Rhabdomyosarcoma (RMS) is a predominantly pediatric soft-tissue cancer where the tumor cells exhibit characteristics of the developing skeletal muscle, and the two most common sub-types are embryonal and alveolar RMS. Elevated activation of the receptor tyrosine kinase (RTK) MET is frequent in RMS and is thought to cause increased tumor metastasis and lack of differentiation. However, the reasons underlying dysregulated MET expression and activation in RMS are not well understood. Therefore, we explored the role of Sprouty 2 (SPRY2), a modulator of RTK signaling, in regulating MET. We identify SPRY2 as a novel MET interactor that colocalizes with and binds MET in both embryonal and alveolar RMS. We find that depletion of SPRY2 leads to MET degradation, resulting in reduced migratory and clonogenic potential, and induction of differentiation in both embryonal and alveolar RMS, outcomes that are identical to depletion of MET. Activation of the ERK/MAPK pathway, known to be crucial for regulating cell migration and whose inhibition is required for myogenic differentiation, was downregulated upon depletion of MET or SPRY2. This provides a direct connection to the decreased migration and induction of differentiation upon depletion of MET or SPRY2. Thus, these data indicate that SPRY2 interacts with MET and stabilizes it in order to maintain signaling downstream of MET, which keeps the ERK/MAPK pathway active, resulting in metastatic potential and inhibition of differentiation in RMS. Our results identify a novel mechanism by which MET signaling is stabilized in RMS, and is a potential target for therapeutic intervention in RMS.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[St] Status:In-Data-Review
[do] DOI:10.1038/s41419-018-0261-2

  3 / 15812 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29318365
[Au] Autor:Schmidt A; Warmann SW; Urla C; Fuchs J
[Ad] Address:Abteilung für Kinderchirurgie und Kinderurologie, Klinik für Kinder- und Jugendmedizin, Universitätsklinikum Tübingen, Hoppe-Seyler-Straße 3, 72076, Tübingen, Deutschland. andreas.schmidt@med.uni-tuebingen.de.
[Ti] Title:Innovationen in der chirurgischen Behandlung solider Tumoren im Kindesalter. [Innovations in surgical treatment of pediatric solid tumors].
[So] Source:Chirurg;89(3):205-211, 2018 Mar.
[Is] ISSN:1433-0385
[Cp] Country of publication:Germany
[La] Language:ger
[Ab] Abstract:The overall survival of children with solid tumors has shown a substantial increase in the past decades due to progress in all of the disciplines involved in the treatment. The poor prognosis for advanced stages of disease and the morbidity related to therapeutic procedures are still a challenge. Innovations in the surgical treatment of solid tumors can contribute to increase the survival rate of affected children and to decrease the treatment-related morbidity. Considering these aspects, the successful implementation of innovations is described based on four examples. (1) Tumor nephrectomy has long been the standard surgical procedure for Wilms tumor/nephroblastoma. Modifications of the surgical technique allow a nephron-sparing resection of the tumor and thereby reducing the long-term effects of nephrectomy. (2) According to the protocols of the International Society of Pediatric Oncology (SIOP) liver transplantation should be used for high-risk hepatoblastoma. Virtual imaging methods based on new software processors enable a more accurate and individual planning of the surgical procedure and an organ-saving extended tumor resection which avoids a transplantation. (3) Mutilating surgical procedures are sometimes necessary for a curative treatment of rhabdomyosarcoma. By combining surgery and brachytherapy mutilating surgical procedures for urogenital rhabdomyosarcomas can be avoided. (4) Pulmonary metastatic nodules can become accessible to minimally invasive resection if CT-guided marking by coil wire is preoperatively performed. In selected cases thoracotomy will be avoided and due to a shorter postoperative course, the time to the subsequent adjuvant chemotherapy will be reduced.
[Pt] Publication type:ENGLISH ABSTRACT; JOURNAL ARTICLE; REVIEW
[Em] Entry month:1801
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[St] Status:In-Data-Review
[do] DOI:10.1007/s00104-017-0568-z

  4 / 15812 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29514840
[Au] Autor:Deel MD; Slemmons KK; Hinson AR; Genadry KC; Burgess BA; Crose LES; Kuprasertkul N; Oristian KM; Bentley RC; Linardic CM
[Ad] Address:Pediatric Hematology/Oncology, Duke University Medical Center.
[Ti] Title:The transcriptional co-activator TAZ is a potent mediator of alveolar rhabdomyosarcoma tumorigenesis.
[So] Source:Clin Cancer Res;, 2018 Mar 07.
[Is] ISSN:1078-0432
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:PURPOSE: Alveolar rhabdomyosarcoma (aRMS) is a childhood soft tissue sarcoma driven by the signature PAX3-FOXO1 (P3F) fusion gene. 5-year survival for aRMS is <50%, with no improvement in over four decades. Although the transcriptional co-activator TAZ is oncogenic in carcinomas, the role of TAZ in sarcomas is poorly understood. The aim of this study was to investigate the role of TAZ in P3F-aRMS tumorigenesis. EXPERIMENTAL DESIGN: After determining from public datasets that TAZ is upregulated in human aRMS transcriptomes, we evaluated whether TAZ is also upregulated in our myoblast-based model of P3F-initiated tumorigenesis, and performed IHC staining of 63 human aRMS samples from tissue microarrays. Using constitutive and inducible RNAi, we examined the impact of TAZ loss-of-function on aRMS oncogenic phenotypes in vitro and tumorigenesis in vivo. Last, we performed pharmacological studies in aRMS cell lines using porphyrin compounds, which interfere with TAZ-TEAD transcriptional activity. RESULTS: TAZ is upregulated in our P3F-initiated aRMS model, and aRMS cells and tumors have high nuclear TAZ expression. In vitro, TAZ suppression inhibits aRMS cell proliferation, induces apoptosis, supports myogenic differentiation, and reduces aRMS cell stemness. TAZ-deficient aRMS cells are enriched in G2/M. In vivo, TAZ suppression attenuates aRMS xenograft tumor growth. Preclinical studies show decreased aRMS xenograft tumor growth with porphyrin compounds alone and in combination with vincristine. CONCLUSIONS: TAZ is oncogenic in aRMS sarcomagenesis. While P3F is currently not therapeutically tractable, targeting TAZ could be a promising novel approach in aRMS.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[St] Status:Publisher

  5 / 15812 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29214757
[Au] Autor:Lee DH; Park CJ; Jang S; Cho YU; Seo JJ; Im HJ; Koh KN; Cho KJ; Song JS; Seo EJ
[Ad] Address:Department of Laboratory Medicine, Gyeongsang National University Hospital, Jinju, Korea.
[Ti] Title:Clinical and Cytogenetic Profiles of Rhabdomyosarcoma with Bone Marrow Involvement in Korean Children: A 15-Year Single-Institution Experience.
[So] Source:Ann Lab Med;38(2):132-138, 2018 Mar.
[Is] ISSN:2234-3814
[Cp] Country of publication:Korea (South)
[La] Language:eng
[Ab] Abstract:BACKGROUND: Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children. Alveolar RMS (ARMS) is characterized by FOXO1-related chromosomal translocations that result in a poorer clinical outcome compared with embryonal RMS (ERMS). Because the chromosomal features of RMS have not been comprehensively defined, we analyzed the clinical and laboratory data of childhood RMS patients and determined the clinical significance of chromosomal abnormalities in the bone marrow. METHODS: Fifty-one Korean patients with RMS <18 years of age treated between 2001 and 2015 were enrolled in this study. Clinical factors, bone marrow and cytogenetic results, and overall survival (OS) were analyzed. RESULTS: In total, 36 patients (70.6%) had ERMS and 15 (29.4%) had ARMS; 80% of the ARMS patients had stage IV disease. The incidences of bone and bone marrow metastases were 21.6% and 19.6%, respectively, and these results were higher than previously reported results. Of the 40 patients who underwent bone marrow cytogenetic investigation, five patients had chromosomal abnormalities associated with the 13q14 rearrangement. Patients with a chromosomal abnormality (15 vs 61 months, P=0.037) and bone marrow involvement (17 vs 61 months, P=0.033) had a significantly shorter median OS than those without such characteristics. Two novel rearrangements associated with the 13q14 locus were detected. One patient with concomitant MYCN amplification and PAX3/FOXO1 fusion showed an aggressive clinical course. CONCLUSIONS: A comprehensive approach involving conventional cytogenetics and FOXO1 FISH of the bone marrow is needed to assess high-risk ARMS patients and identify novel cytogenetic findings.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1712
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[St] Status:In-Process
[do] DOI:10.3343/alm.2018.38.2.132

  6 / 15812 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29512925
[Au] Autor:Yagci-Küpeli B; Uluç S; Külahçi Ö
[Ad] Address:Department of Pediatric Hematology/Oncology, Adana City Education and Research Hospital, Saglik Bilimleri University, Adana, Turkey.
[Ti] Title:Isolated central nervous system relapse of maxillary rhabdomyosarcoma presenting with neoplastic meningitis.
[So] Source:Pediatr Blood Cancer;, 2018 Mar 07.
[Is] ISSN:1545-5017
[Cp] Country of publication:United States
[La] Language:eng
[Pt] Publication type:LETTER
[Em] Entry month:1803
[Cu] Class update date: 180307
[Lr] Last revision date:180307
[St] Status:Publisher
[do] DOI:10.1002/pbc.27029

  7 / 15812 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29254918
[Au] Autor:Tong B; Zhang L; Li GP
[Ad] Address:State Key of Laboratory of Reproductive Regulation and Breeding of Grassland Livestock, Inner Mongolia University, Huhhot 010071, China.
[Ti] Title:Progress in the molecular and genetic modification breeding of beef cattle in China.
[So] Source:Yi Chuan;39(11):984-1015, 2017 Nov 20.
[Is] ISSN:0253-9772
[Cp] Country of publication:China
[La] Language:eng
[Ab] Abstract:The studies of beef cattle breeding in China have been greatly improved with the rapid development of the international beef cattle industrialization. The beef cattle breeding technologies have rapidly transformed from traditional breeding to molecular marker-assisted breeding, genomic selection and genetic modification breeding. Hundreds of candidate genes and molecular markers associated with growth, meat quality, reproduction performance and diseases resistance have been identified, and some of them have already been used in cattle breeding. Genes and molecular markers associated with growth and development are focused on the growth hormone, muscle regulatory factors, myostatin and insulin-like growth factors. Meat quality is mediated by fatty acid transport and deposition related signals, calpains and calpain system, muscle regulatory factors and muscle growth regulation pathways. Reproduction performance is regulated by GnRH-FSH-LH, growth differentiation factor 9, prolactin receptor and forkhead box protein O1. Disease resistance is modulated by the major histocompatibility complex gene family, toll-like receptors, mannose-binding lectin and interferon gene signals. In this review, we summarize the most recent progress in beef cattle breeding in marker-assisted selection, genome-wide selection and genetic modification breeding, aiming to provide a reference for further genetic breeding research of beef cattle in China.
[Mh] MeSH terms primary: Breeding
Cattle/genetics
Meat
[Mh] MeSH terms secundary: Animals
DNA Methylation
Forkhead Box Protein O1/genetics
Mannose-Binding Lectin/genetics
Receptors, FSH/genetics
Selection, Genetic
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Nm] Name of substance:0 (Forkhead Box Protein O1); 0 (Mannose-Binding Lectin); 0 (Receptors, FSH)
[Em] Entry month:1803
[Cu] Class update date: 180306
[Lr] Last revision date:180306
[Js] Journal subset:IM
[Da] Date of entry for processing:171220
[St] Status:MEDLINE
[do] DOI:10.16288/j.yczz.17-181

  8 / 15812 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 29237527
[Au] Autor:Xie Y; Zhao WH; Hua Y; Sun Q; Wu PH
[Ad] Address:Department of Pediatrics, Peking University First Hospital, Beijing 100034, China. zhaowh3212@126.com.
[Ti] Title:[A rhabdomyosarcoma patient from a Li-Fraumeni syndrome family: a case report and literature review].
[So] Source:Zhongguo Dang Dai Er Ke Za Zhi;19(12):1263-1266, 2017 Dec.
[Is] ISSN:1008-8830
[Cp] Country of publication:China
[La] Language:chi
[Ab] Abstract:Li-Fraumeni syndrome (LFS) is a hereditary cancer predisposition syndrome, with the characteristics of early onset of cancer and high cancer incidence. TP53 is widely accepted as a pathogenic gene of LFS. A 2 years and 6 months old boy is reported in this article, who was diagnosed with embryonal rhabdomyosarcoma (RMS) in the left submandibular region. His brother died of RMS, and his grandmother was diagnosed with breast cancer. TP53 gene mutation detection was performed in this patient and some family members, indicating a missense mutation in exon 8 of the patient: c.844C>T (p.Arg282Trp, heterozygous). TP53 mutation was also found in his mother and sister. The boy met the diagnostic criteria for LFS. Among pediatric patients, the most common LFS diseases include osteosarcoma, adrenocortical cancer, central nervous system tumor, and soft tissue tumor. Additionally, leukemia and lymphoma are also involved. LFS patients have a high risk to suffer secondary or even multiple cancers. Therefore, it is necessary to perform genetic detection for pediatric cancer patients, especially those with hereditary predisposition cancers. TP53 mutation often indicates poor prognosis, so it is important to take active treatment and systematic monitoring for LFS family.
[Mh] MeSH terms primary: Li-Fraumeni Syndrome/genetics
Rhabdomyosarcoma/genetics
[Mh] MeSH terms secundary: Child, Preschool
Genes, p53
Humans
Male
Mutation
[Pt] Publication type:CASE REPORTS; JOURNAL ARTICLE; REVIEW
[Em] Entry month:1803
[Cu] Class update date: 180306
[Lr] Last revision date:180306
[Js] Journal subset:IM
[Da] Date of entry for processing:171215
[St] Status:MEDLINE

  9 / 15812 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29509095
[Au] Autor:Lang A; Dehner LP
[Ad] Address:a Lauren V. Ackerman Laboratory of Surgical Pathology, Barnes-Jewish Hospital/St. Louis Children's Hospital , Washington University Medical Center , St. Louis , Missouri , USA.
[Ti] Title:Delayed Metastasis of Clear Cell Sarcoma of Kidney to Bladder After 7 Disease-Free Years.
[So] Source:Fetal Pediatr Pathol;:1-8, 2018 Mar 06.
[Is] ISSN:1551-3823
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:INTRODUCTION: Clear cell sarcoma of the kidney (CCSK) is childhood neoplasm with its own distinctive pattern of metastasis and may appear after a disease free interval of 5 years or more. MATERIALS AND METHODS: Histopathology and immunohistochemistry were available from the radical nephrectomy and the later partial cystectomy, which was performed after a seven disease-free interval. RESULTS: The pathologic features of the primary tumor were those of a classic CCSK with a monotypic pattern of uniform rounded to ovoid tumor cells with a background network of delicate blood vessels. By contrast, the bladder recurrence had a myxoid hypocellular appearance (one of the known variant patterns of CCSK). Both tumors displayed immunopositivity for Cyclin-D1 and CD117 with a less intense reaction in the bladder metastasis. CONCLUSIONS: This case demonstrates that CCSK has the potential to metastasize after a prolonged disease-free interval and may have deceptively bland histopathologic features.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180306
[Lr] Last revision date:180306
[St] Status:Publisher
[do] DOI:10.1080/15513815.2018.1435757

  10 / 15812 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 29506850
[Au] Autor:Hamilton EC; Miller CC; Joseph M; Huh WW; Hayes-Jordan AA; Austin MT
[Ad] Address:Department of Pediatric Surgery, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, Texas; Center for Surgical Trials and Evidence-Based Practice, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, Texas.
[Ti] Title:Retroperitoneal lymph node staging in paratesticular rhabdomyosarcoma-are we meeting expectations?
[So] Source:J Surg Res;224:44-49, 2018 Apr.
[Is] ISSN:1095-8673
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:BACKGROUND: Staging retroperitoneal lymph node dissection (RPLND) for paratesticular rhabdomyosarcoma (RMS) is recommended for all patients aged ≥10 y. The purpose of this study was to evaluate adherence with surgical resection guidelines for RPLND in patients with paratesticular RMS as a measure for surgical quality. MATERIALS AND METHODS: All patients with paratesticular RMS were identified in the Surveillance, Epidemiology, and End Results database from 1973 to 2012. Patients were divided into two eras to reflect before (1973-2002) and after (2003-2012) the release and dissemination of the 2001 surgical guidelines for staging ipsilateral RPLND in all patients aged ≥10 y with paratesticular RMS. Survival outcomes associated with lymph node dissection were calculated using the Kaplan-Meier method and Cox proportional hazards analysis. RESULTS: Two hundred thirty-five patients with paratesticular RMS were identified and included in the study, among whom 111 were adolescents aged 10-20. RPLND did not significantly increase after 2003 among adolescents (45%-61%, P = 0.09). The benefit of RPLND on improved 5-y overall survival was evident among adolescents (92% versus 64%, P = 0.003). Adjusting for histology, age, stage at diagnosis, and race/ethnicity, RPLND was associated with improved overall survival among patients aged ≥10 y (hazard ratio 0.37, 95% confidence interval 0.17-0.83). CONCLUSIONS: Despite surgical guidelines recommending RPLND in pediatric patients aged ≥10 y, nearly one-third of adolescent patients did not undergo RPLND. These findings are disturbing considering the survival benefit associated with RPLND among adolescent patients and indicate an opportunity for improvement in surgical quality.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180306
[Lr] Last revision date:180306
[St] Status:In-Data-Review


page 1 of 1582 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information